Concert Pharmaceuticals Presents Positive 48-Week Results from Phase 2 … – The Herald | HeraldOnline.com (press release)

Concert Pharmaceuticals Presents Positive 48-Week Results from Phase 2
The Herald | HeraldOnline.com (press release)
LAS VEGASConcert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced 48-week results of its Phase 2 clinical trial of CTP-499 in patients with diabetic kidney disease. CTP-499, when used in addition to the standard of care, is being developed to …
Drug Misses Mark, but May Do Some Good in Diabetic NephropathyMedPage Today

all 5 news articles

…read more

Source: Las Vegas Concert News From Google News

Leave a Comment